Wilson Sonsini Goodrich & Rosati advised Acumen Pharmaceuticals on the deal.Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
